JP2011526693A - 転移に関連する徴候および決定因子、ならびにそれらの使用方法 - Google Patents

転移に関連する徴候および決定因子、ならびにそれらの使用方法 Download PDF

Info

Publication number
JP2011526693A
JP2011526693A JP2011516713A JP2011516713A JP2011526693A JP 2011526693 A JP2011526693 A JP 2011526693A JP 2011516713 A JP2011516713 A JP 2011516713A JP 2011516713 A JP2011516713 A JP 2011516713A JP 2011526693 A JP2011526693 A JP 2011526693A
Authority
JP
Japan
Prior art keywords
determinant
tumor
subject
metastatic
determinants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011516713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526693A5 (https=
Inventor
リンダ チン，
ケネス エル． スコット，
パピア ゴーシュ，
Original Assignee
ディナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical ディナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2011526693A publication Critical patent/JP2011526693A/ja
Publication of JP2011526693A5 publication Critical patent/JP2011526693A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011516713A 2008-06-26 2009-06-26 転移に関連する徴候および決定因子、ならびにそれらの使用方法 Withdrawn JP2011526693A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7593308P 2008-06-26 2008-06-26
US61/075,933 2008-06-26
PCT/US2009/048862 WO2009158620A2 (en) 2008-06-26 2009-06-26 Signatures and determinants associated with metastasis methods of use thereof

Publications (2)

Publication Number Publication Date
JP2011526693A true JP2011526693A (ja) 2011-10-13
JP2011526693A5 JP2011526693A5 (https=) 2012-05-31

Family

ID=41445345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011516713A Withdrawn JP2011526693A (ja) 2008-06-26 2009-06-26 転移に関連する徴候および決定因子、ならびにそれらの使用方法

Country Status (14)

Country Link
US (1) US20110182881A1 (https=)
EP (1) EP2307886A2 (https=)
JP (1) JP2011526693A (https=)
KR (1) KR20110036056A (https=)
CN (1) CN102132160A (https=)
AU (1) AU2009262022A1 (https=)
BR (1) BRPI0914734A2 (https=)
CA (1) CA2728674A1 (https=)
IL (1) IL210245A0 (https=)
MX (1) MX2010014280A (https=)
NZ (1) NZ590385A (https=)
RU (1) RU2011102743A (https=)
WO (1) WO2009158620A2 (https=)
ZA (1) ZA201100225B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US20100248269A1 (en) * 2009-03-30 2010-09-30 New York Blood Center Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer
SG183304A1 (en) 2010-02-17 2012-09-27 Takeda Pharmaceutical Heterocyclic compound
RU2012157998A (ru) 2010-06-01 2014-07-20 Тодос Медикал Лтд. Диагностика рака
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US8880457B2 (en) * 2010-11-05 2014-11-04 Allegheny-Singer Research Institute Method and system for recommending a decision based on combined entity modeling
WO2012153326A1 (en) 2011-05-11 2012-11-15 Todos Medical Ltd. Diagnosis of cancer
US20140302042A1 (en) * 2011-07-01 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
WO2013036620A1 (en) * 2011-09-06 2013-03-14 Becton, Dickinson And Company Methods and compositions for cytometric detection of rare target cells in a sample
CN104684398A (zh) 2012-08-31 2015-06-03 索隆-基特林癌症研究协会 粒子、方法以及其用途
JP6164678B2 (ja) * 2012-10-23 2017-07-19 国立研究開発法人科学技術振興機構 ネットワークエントロピーに基づく生体の状態遷移の予兆の検出を支援する検出装置、検出方法及び検出プログラム
CA2891653A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP6465811B2 (ja) 2012-12-19 2019-02-06 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 多様式の粒子、方法およびその使用
EP2958481A4 (en) 2013-02-20 2017-03-08 Sloan-Kettering Institute for Cancer Research Wide field raman imaging apparatus and associated methods
CA2904283A1 (en) 2013-03-14 2014-10-02 Castle Biosciences, Inc. Methods for predicting risk of metastasis in cutaneous melanoma
ES2877332T3 (es) 2013-05-28 2021-11-16 Todos Medical Ltd Un método para indicar la presencia de tumores benignos mediante el uso de una muestra de células mononucleares de sangre periférica (PBMC)
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
AU2015225867B2 (en) * 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2016018896A1 (en) 2014-07-28 2016-02-04 Memorial Sloan Kettering Cancer Center Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes
US11009467B2 (en) * 2015-02-17 2021-05-18 Siemens Healthcare Diagnostics Inc. Model-based methods and apparatus for classifying an interferent in specimens
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
WO2017004301A1 (en) 2015-07-01 2017-01-05 Memorial Sloan Kettering Cancer Center Anisotropic particles, methods and uses thereof
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
TWI725248B (zh) * 2016-10-28 2021-04-21 茂英基因科技股份有限公司 辨識轉移性腫瘤的原發位置之方法及系統
TWI676688B (zh) * 2017-07-17 2019-11-11 茂英基因科技股份有限公司 辨識細胞種類型之方法及系統
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
JP7580210B2 (ja) * 2020-06-15 2024-11-11 三菱重工業株式会社 予兆判定装置、予兆判定方法及びプログラム
EP4405507A4 (en) * 2021-09-20 2025-11-05 Droplet Biosciences Inc METHODS FOR DISEASE ASSESSMENT USING A DRAINAGE FLUID
EP4445137A4 (en) * 2021-12-08 2025-12-10 Mayo Found Medical Education & Res MELANOMA ASSESSMENT AND TREATMENT
CN116204890B (zh) * 2023-04-28 2023-07-21 浙江鹏信信息科技股份有限公司 一种自适应增强人工智能算法安全的算法组件库
CN117171678B (zh) * 2023-11-02 2024-01-12 北京建工环境修复股份有限公司 一种微生物修复过程中土壤微生物菌群调控方法及系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (en) * 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Packaging material having excellent seal packaging property
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) * 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5018067A (en) * 1987-01-12 1991-05-21 Iameter Incorporated Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US20020038227A1 (en) * 2000-02-25 2002-03-28 Fey Christopher T. Method for centralized health data management
EP2135960A1 (en) * 2001-09-19 2009-12-23 Intergenetics Incorporated Genetic analysis for stratification of cancer risk by determining the allelic profile of the VDR-ApaI and CYP11B2 genes
US20040122296A1 (en) * 2002-12-18 2004-06-24 John Hatlestad Advanced patient management for triaging health-related data
US7468032B2 (en) * 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US20030232398A1 (en) * 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
WO2005108621A1 (en) * 2004-04-30 2005-11-17 Yale University Methods and compositions for cancer diagnosis
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
WO2007059313A1 (en) * 2005-11-16 2007-05-24 Children's Medical Center Corporation Method to assess breast cancer risk
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20090069196A1 (en) * 2006-03-22 2009-03-12 Mathias Gehrmann Prediction of Breast Cancer Response to Chemotherapy
PT2062049E (pt) * 2006-09-06 2014-07-28 Univ California Diagnóstico molecular e classificação de melanoma maligno
WO2008082730A2 (en) * 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
CA2668831A1 (en) * 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
CA2680692A1 (en) * 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer
AU2008316319A1 (en) * 2007-10-23 2009-04-30 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms
AU2009213689B2 (en) * 2008-02-14 2014-11-20 Decode Genetics Ehf. Susceptibility variants for lung cancer
WO2009124251A1 (en) * 2008-04-03 2009-10-08 Sloan-Kettering Institute For Cancer Research Gene signatures for the prognosis of cancer
EP2288728A4 (en) * 2008-05-15 2011-11-02 Univ Southern California GENOTYP AND EXPRESSION ANALYSIS FOR USE IN PROGNOSIS AND THERAPY SELECTION
MX337650B (es) * 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.

Also Published As

Publication number Publication date
AU2009262022A1 (en) 2009-12-30
IL210245A0 (en) 2011-03-31
KR20110036056A (ko) 2011-04-06
EP2307886A2 (en) 2011-04-13
MX2010014280A (es) 2011-05-23
NZ590385A (en) 2012-11-30
US20110182881A1 (en) 2011-07-28
CA2728674A1 (en) 2009-12-30
WO2009158620A3 (en) 2010-06-03
CN102132160A (zh) 2011-07-20
BRPI0914734A2 (pt) 2015-10-20
ZA201100225B (en) 2011-10-26
WO2009158620A2 (en) 2009-12-30
RU2011102743A (ru) 2012-08-10

Similar Documents

Publication Publication Date Title
JP2011526693A (ja) 転移に関連する徴候および決定因子、ならびにそれらの使用方法
Dinh et al. Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube
Chen et al. Gene expression patterns in human liver cancers
AU2021212151B2 (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
Chundong et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis
JP2011528442A (ja) 前立腺癌に関連した兆候およびｐｃｄｅｔｅｒｍｉｎａｎｔ、ならびにそれらの使用方法
US20140302042A1 (en) Methods of predicting prognosis in cancer
JP2019537108A (ja) 癌の分類および予後
EP2723905A1 (en) Signatures and determinants associated with prostate cancer progression and methods of use thereof
WO2015073949A1 (en) Method of subtyping high-grade bladder cancer and uses thereof
CA3096529A1 (en) Improved classification and prognosis of prostate cancer
US20130143753A1 (en) Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
Guel et al. Identification of cytokeratin24 as a tumor suppressor for the management of head and neck cancer
EP2721178B1 (en) Method for the prognosis of breast cancer based on expression markers
KR20210016362A (ko) 결장암 예측 바이오마커로서의 l1td1
US9606122B2 (en) Prognosis of oesophageal and gastro-oesophageal junctional cancer
WO2022082317A1 (en) Gene signature for predicting progression and progress of urinary cancers and methods of use thereof
KR20260043982A (ko) 폐 선암의 조직병리학적 아형 식별 및 예후 예측을 위한 바이오마커 및 이의 용도
Wei et al. Genetic wiring of the m6A epitranscriptome drives prostate cancer progression
Huang et al. Zinc finger protein 800 (ZNF800) promotes proliferation and migration of lower-grade glioma and is associated with immune infiltration
Young A translational study in pancreatic neuroendocrine neoplasms
KR20240126130A (ko) 대장암 예후 예측용 바이오마커, 및 이를 이용한 예후 예측 방법
CN117568482A (zh) 用于胃癌预后的分子标记物及其应用
CN118661103A (zh) 雌激素受体(er)阳性样和雌激素受体(er)阴性样乳腺癌的蛋白质标志物
Class et al. Patent application title: METHOD FOR THE PROGNOSIS OF BREAST CANCER BASED ON THE EXPRESSION OF THE GENE PIN1 IN COMBINATION WITH MUTATIONS IN THE GENE TP53 Inventors: Giannino Del Sal (Trieste, IT) Marco Napoli (Palermo, IT) Javier Girardini Brovelli (Rosario, AR) Silvano Piazza (Latisana, IT) Alastair Thompson (Auchterarder, GB) Assignees: University of Dundee Universita Degli Studi di Trieste

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120330

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130808